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through 10 months.
Results: Median TpP levels were 8.9 ug/ml (IQR 4.8-15.9). Higher baseline levels of TpP
were associated with older age, hypertension, diabetes, prior CAD, and prior CHF
(p<0.05 for each). TpP levels correlated only weakly with troponin I (TnI), C-reactive pro-
tein (CRP), and B-type natriuretic peptide (BNP) (|r|<0.1 for each). The risk of death, MI,
Urg Revasc, Sev Isch, and the composite increased progressively with rising levels of
TpP (Fig). After adjusting for baseline differences, including TnI, CRP, and BNP, patients
with TpP levels above the median remained at significantly increased risk for the com-
posite endpoint (hazard ratio 1.47, p=0.001).
Conclusion: In patients with ACS, elevated levels of TpP at baseline are associated with
an increased risk of death and ischemic complications. These data support the value of
combining a marker of active thrombosis, such as TpP, with established biomarkers of
necrosis, inflammation, and hemodynamic stress for risk assessment in ACS.
11:30 a.m.
884-5 Impact of Troponin Status and Coronary Artery Disease 
by Angiography on Outcome in Acute Coronary 
Syndrome: A TACTICS TIMI-18 Substudy
Manu Pillai, Peter DiBattiste, Sabina Murphy, David Morrow, Christopher Cannon, Nasser 
M. Lakkis, Baylor College of Medicine, Houston, TX, Brigham and Women's Hospital, 
Boston, MA
Background: Cardiac troponin (Tn) T and I elevations are powerful independent prog-
nostic indicators in the setting of acute coronary syndrome (ACS). However, in clinical
practice, seemingly “false positive” Tn's are common . Methods and Results: To evalu-
ate whether such patients are “false positives” and if there is clinical significance of an
elevated Tn, we evaluated the prognosis of ACS patients enrolled in TACTICS-TIMI-18
study according to the presence or absence of CAD on angiography and Tn status on
admission. In this study 1,372 patients underwent angiography. A subset of 455 patients
were Tn negative, and of those, 362 (79.6%) had significant CAD (>50%stenosis in one
or more vessel). Fifty-seven out of 917 patients (6.2%) with + TnT or I did not have signif-
icant CAD. The mean value of TnT in patients with angiographic CAD was 0.603 ng/ml
compared to 0.281 ng/ml in those without CAD (p=0.01). The mean value of TnI was 9.39
ng/ml in patients with CAD compared to 3.32 ng/ml ( in patients without CAD (p=0.005).
An outcome of death or reinfarction at 6 months is shown in table.
o:p> 
Conclusions: Elevated troponin in ACS confers a significantly high risk for death or MI,
even among patients who are found to not have significant CAD. The mechanism of this
adverse outcome deserves further study, but these data suggest that all patients present-
ing with a clinical history of ACS and a positive troponin at presentation deserve early
and long-term aggressive preventive management.
11:45 a.m.
884-6 Incidence of Vulnerable Plaques in Humans: 
Assessment With 3-D Intravascular Palpography
Johannes A. Schaar, Evelyn Regar, Francesco Saia, Chris L. de Korte, Frits Mastik, 
Anton F. van der Steen, Patrick W. Serruys, Erasmus Medical Center, Rotterdam, The 
Netherlands, Interuniversity Cardiology Institute of the Netherlands, Utrecht, The 
Netherlands
Intravascular palpography (IP) can detect deformable thin-cap fibroatheroma with a high
sensitivity and specificity by measuring the strain of the plaque surface. These vulnerable
plaques show a typical high strain pattern. We hypothesized that it is possible to detect
vulnerable plaques in-vivo in human coronary arteries by scanning the coronary artery
for typical high strain patterns.
Method: IP was performed in 56 patients by using standard 20 MHz intravascular ultra-
sound catheters (Avanar, JOMED Inc). Analysis included the complete length of the ves-
sel. The population was divided into 3 groups: Patients with [1] antecedent (<24h)
myocardial infarction. (post MI) [2] unstable angina (ST depression, Troponin negative);
(unstable). [3] Stable angina (stable). Per patient one coronary artery was investigated.
Results: IP was successful performed in all patients. The number of typical strain pat-
terns reflecting the number of vulnerable plaques per coronary artery are given in the
table. There was a significant difference between the stable vs. unstable group (p<0.001)
and stable vs. post MI group (p<0.0001). No difference was seen between the unstable
group and post MI group (p<0.056). 
Conclusion:
IP can be used to assess the number vulnerable plaques in humans. This pilot study
revealed a clear association between clinical presentation and the amount of vulnerable
plaques. Additional validation has to be performed to assess the predictive value of the
technique to identify vulnerable patients.
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891-1 Enhanced External Counterpulsation Decreases Wave 
Reflection Amplitude and Reduces Left Ventricular 
Afterload and Systolic Stress in Patients With 
Refractory Angina
Wilmer W. Nichols, Randy W. Braith, Rahul Aggarwal, C. R. Conti, University of Florida, 
Gainesville, FL
Background: Myocardial ischemia is associated with increased arterial stiffness which
causes early return of reflected pressure waves from the lower body and augments aortic
systolic and pulse pressures and increases left ventricular afterload and myocardial oxy-
gen demand. The aim of this study was to determine if arterial properties and wave
reflection characteristics are altered after EECP treatment in patients with chronic stable
angina resistant to anti-anginal medication. Methods: High-fidelity radial artery pressure
waveforms were recorded non-invasively by applanation tonometry and ascending aortic
pressure waveforms generated using a mathematical transfer function. Twenty patients
(age 61±7.3 years) with refractory angina taking two or more anti-anginal drugs were
studied. Data were collected before and after 34 one-hour EECP sessions. Augmentation
index (AIa, index of aortic stiffness) and amplitude and timing of the reflected pressure
wave (index of myocardial oxygen demand) were calculated from the generated aortic
pressure waveform. Results: EECP caused a significant decline in AIa from 27±10 to
19±9.8% (p<0.02) and a delay in reflected wave travel time from 68±8.3 to 74±6.8 msec
(p<0.01). These modifications in wave reflection characteristics were associated with a
decline in reflected wave amplitude (from 13±7.2 to 9.0±7.0 mm Hg, p<0.01) and dura-
tion (from 189±34 to 174±40 msec, p<0.01) which caused a decrease in aortic systolic
(from 120±18 to 108±18 mm Hg, p<0.01) and pulse (from 48±15 to 41±16 mm
Hg,p<0.01) pressure. The average number of anginal episodes per week decreased from
7.1±6.0 to 1.1±1.2 (p<0.02) while heart rate, body weight and drug regimen did not
change during the course of the study. Conclusions: EECP treatment delays return of the
reflected pressure wave from the periphery to the heart, reduces its amplitude and,
therefore, decreases aortic blood pressure and systolic stress in patients with refractory
angina taking anti-anginal medication. These changes, which are likely due to decreased
arterial stiffness and pulse wave velocity of the muscular arteries in the legs, reduce myo-
cardial oxygen demand and decrease the number of anginal episodes.
10:45 a.m.
891-2 External Counterpulsation Therapy: Significant Clinical 
Improvement Without Electrophysiologic Remodeling
Charles A. Henrikson, Nisha Chandra-Strobos, Johns Hopkins Medical Institutions, 
Baltimore, MD
Background: External counterpulsation therapy (ECP) non-invasively improves coronary
flow, hemodynamics, and time to ischemia in patients with severe coronary artery dis-
ease (CAD). Other treatments with similar effects, e.g. left ventricular assist devices, pro-
mote electrophysiologic remodeling, with a narrowing of the QRS complex.
Methods: We studied 28 patients, who completed a 7 week 35 hour session of ECP, to
assess whether such therapy would also result in electrophysiological remodeling, espe-
cially if associated with clinical improvement. All patients had class II-III angina, imaging-
proven ischemia, and severe CAD.
Results: Of 28 patients, with mean age 62+/-13 years (mean +/-SD), 78% were male,
46% diabetic, 82% hypertensive, 60% had undergone angioplasty, and 67% bypass sur-
gery. The mean ejection fraction was 44% (range 25-60%). Following ECP, most patients
(82%) had at least a one full class improvement in their anginal pattern. In most patients,
there was substantial baseline conduction system disease present: a mean QRS of 105
+/- 19 msec. Of note, there was no significant change in heart rate, PR, QRS, or QTc
intervals before and after ECP in either clinical responders or non-responders. When
Tn neg,
no CAD
n=93
Tn pos
no CAD
n=57
Tn neg
CAD
n=362
Tn pos
CAD
n=860
p-value
Death 0% 1.75% 2.21% 4.07% 0.082
MI 0% 3.51% 4.42% 8.26% 0.003
death or MI 0% 5.26% 5.52% 11.16% <0.001
Stable Unstable Post MI
n (patients) 19 19 18
High strain spots 0.7 ± 0.5 1.7 ± 0.4 2.0 ± 0.8
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analyzed by response to ECP, ejection fraction, or history of revascularization, there were
still no detectable changes in EKG parameters (all p=NS).
Conclusion: While ECP is an effective treatment for severe CAD, it does not prompt early
electrical remodeling of the heart.
11:00 a.m.
891-3 Enhanced External Counterpulsation Improves 
Functional Capacity and Quality of Life in Women With 
Chronic Angina
Georgiann C. Linnemeier, Elizabeth D. Kennard, Ozlem Soran, Sheryl F. Kelsey, 
University of Pittsburgh, Pittsburgh, PA
Background: Within the population of the United States, 36% of women aged 55-64
years are disabled by clinical manifestations of coronary heart disease, with disability
rates of 55% for women over 75 years of age. We examined the therapeutic efficacy of
EECP on functional status and quality of life in women with chronic angina as assessed
by the Duke Activity Status Index (DASI), a standardized assessment that correlates well
with peak oxygen uptake (Spearman correlation coefficient, 0.58).
Methods: Demographic and clinical outcome data were analyzed on all patients enrolled
in the International EECP Patient Registry-2 who had baseline and post-treatment DASI
scores (N=524). Linear regression model analyses were used to examine independent
predictors of DASI scores.
Results: Baseline characteristics of the study group were: mean age- 68 years, female-
27%, duration of CHD-12 years, prior myocardial infarction- 71%, history of diabetes-
42%, and history of congestive heart failure (CHF)- 32%. Angina was classified as Cana-
dian Cardiovascular Society class III or IV in 90% of patients. Patients experienced a
mean of 11 episodes of angina/week despite optimum medical management and previ-
ous cardiac revascularization. Pre-treatment, the mean DASI score was 12 (of a possible
58.2); with females scoring 8.7 and males scoring 13.7 (p<0.001). Post-treatment, the
mean DASI score was 17.9. Females scored 15.4 and males scored 18.8 (p<0.01). Lin-
ear regression analysis demonstrated that female gender, history of CHF, prior coronary
artery bypass surgery, and class III/IV angina were independent predictors of low DASI
scores pre-treatment. Age, diabetes and history of CHF were associated with a lower
post-treatment score. Female gender was not independently associated with a lower
score post-treatment.
Conclusion: This study demonstrates that, even with adjustment for comorbidities, there
is more functional disability among female patients with chronic angina than with male
patients. EECP improves functional capacity and quality of life as assessed by the DASI
questionnaire with no gender disparity.
11:15 a.m.
891-4 The Effects of Enhanced External Counterpulsation on 
Myocardial Perfusion in Patients With Stable Angina: A 
Single-Blind Multicenter Pilot Study
Andrew D. Michaels, Ajit Raisinghani, Ozlem Soran, Paul-Andre de Lame, Michele L. 
Lemaire, Paul Kligfield, Denny D. Watson, George Beller, University of California, San 
Francisco, San Francisco, CA, University of Virginia, Charlottesville, VA
Introduction: Enhanced external counterpulsation (EECP) has been shown to reduce
angina and improve exercise tolerance and quality of life (QOL) in patients with angina.
However, the mechanism of these effects is unclear. We sought to determine whether
EECP improves exercise-induced myocardial perfusion. Methods: Patients with class II-
IV angina and exercise-induced reversible perfusion defects were enrolled from 5 US
centers. QOL was assessed using SF-36 and Seattle Angina Questionnaires prior to and
1-month after 35-hours of EECP. Symptom-limited quantitative gated technetium-99m-
sestamibi SPECT exercise perfusion imaging was performed prior to and 1-month post-
EECP. Sestamibi was injected at the same heart rate in both stress tests. Exercise tests
and SPECT images were read at core laboratories blind to the origin and time of the
tests. Myocardial segments with partially or completely reversible perfusion defects on
the pre-EECP study were flagged as target segments. Results: Of 37 patients enrolled,
34 completed pre- and post-EECP stress testing. The mean age was 61±10 years, 81%
were male, 78% has prior revascularization, and 68% had 3-vessel disease. The mean
angina class decreased from 2.7±0.7 at baseline to 1.7±0.7 after EECP (p<0.0001). QOL
by both the SF-36 and SAQ improved after EECP (p<0.001). Exercise duration increased
from 9.1±3.7 min at baseline to 10.2±3.6 min post-EECP (p=0.03). The average percent
tracer uptake of target segments pre- vs post-EECP following stress was 64.5±11.3 vs
63.3±13.2 (p=0.34) and at rest was 74.8±10.4 vs 72.7±9.9 (p=0.05). Reversibility (rest-
stress) was 10.3±6.8 vs 9.4±8.1 (p=0.51). Average thickening fractions in target seg-
ments were 28.8±11.1 vs 26.9±13.3 (p=0.32). Conclusions: We confirm previous work
that EECP reduces angina, improves exercise capacity, and improves QOL. A training
effect with peripheral changes occurred after EECP. There were no significant changes in
mean defect magnitude, amount of reversibility, and thickening fractions measured using
myocardial quantitative SPECT imaging when compared at identical pre- and post-EECP
heart rates. These data do not preclude balanced changes in global myocardial perfu-
sion.
11:30 a.m.
891-5 Frequency and Results of Repeat Enhanced External 
Counterpulsation for Refractory Angina
William E. Lawson, Gregory Barsness, Ozlem Soran, Elizabeth D. Kennard, John C. Hui, 
SUNY Stony Brook, Stony Brook, NY, University of Pittsburgh, Pittsburgh, PA
Background: Enhanced external counterpulsation (EECP) relieves angina in most
patients (pts). However, angina may not respond or may reoccur necessitating repeat
EECP.
Purpose: To investigate EECP retreatment frequency, pt characteristics, retreatment
course and response.
Methods: Sequential refractory angina pts, enrolled in the International EECP Pt Regis-
try with 1 year follow-up post initial EECP therapy were examined. A Cox Proportional
Hazards model was used to determine independent predictors of return for treatment
within one year.
Results: Of 2,255 IEPR pts, 233 (10%) repeated EECP within 14 months. Mean age was
66.3 ± 10.9 years, 93.7% white, 73.4% male. By history, 68.8% had prior MI and 32.8%
CHF. Risk factors included: DM 40.7%, HBP 70.7%, hyperlipidemia 82.3%, smoking
71.3%. The mean EF was 47.0 ± 14.4 %; 18.5% had an EF < 35%. Only 14.8% were PCI
or CABG candidates. At baseline, 85.9% had CCS class III/IV angina. Pts received 33.5
± 9.5 hrs of EECP; 83.7% completed therapy. Post EECP 74% improved angina by 1 or
more CCS classes; 28.7% remained CCS III/IV. Of the returning pts, 215 had full data
available. Mean time to return was 168 ± 129 days. Retreatment reasons included:
angina increase (27.8%), persistent angina (34.2%), completing an incomplete initial
course (38.1%). At retreatment 78.3% had CCS class III/IV angina. Treatment averaged
26.4 ± 12.6 hrs; 77.1% completed therapy. Post retreatment angina was reduced by one
or more classes in 71.4%; 30.8% had class III/IV angina. In pts completing their initial
course, major retreatment predictors of were: prior CABG (RR 1.63: CI 1.07-2.49), prior
PCI (RR 1.69: CI 1.13-2.52), HBP (RR 1.63: CI 1.08-2.46). In pts with an incomplete ini-
tial treatment, lack of anginal reduction predicted return (RR 2.19: CI 1.28-3.75).
Conclusions: Retreatment occurred in 6.2% of pts for persistent or worsening angina
and in 3.8% for an incomplete initial course. EECP was similarly effective as initial and
subsequent therapy. Return was predicted by prior revascularization and HBP in pts
completing the initial course of EECP and by lack of angina reduction in pts with an
incomplete initial course.
11:45 a.m.
891-6 Long-Term Improvement in Microvascular Angina 
Patients Treated With Enhanced External 
Counterpulsation
Kenneth D. Kronhaus, William E. Lawson, Lake Cardiology, Mount Dora, FL, SUNY Stony 
Brook, Stony Brook, NY
Background: Angina in patients without significant angiographic epicardial disease can
be a medically refractory cause of chronic disability. For these microvascular angina
patients Enhanced External Counterpulsation (EECP) may prove uniquely beneficial.
Patent epicardial arteries facilitate transmission of the increased flow and pressure gen-
erated by EECP to the microcirulation and may promote angiogenesis, normalize endot-
helial function and improve myocardial perfusion and anginal symptoms. The benefit and
durability of EECP therapy in these patients was studied.
Methods: Patients with typical angina refractory to medical therapy and evidence of
microvascular angina (a pharmacologic or exercise stress test with radionuclide or
echocardiographic imaging [ST] showing regional ischemia together with a cardiac
angiogram demonstrating no significant coronary disease) were treated with EECP.
Angina, assessed by the Canadian Cardiovascular Society class [CCS], and stress tests
were evaluated at baseline and after completing EECP treatment. Major cardiovascular
events (cardiac hospitalization, death, infarction) were tracked for the duration of follow-
up. Statistical analysis was performed with the student t test; significance level p <0.05.
Results: Twenty one pts, 14 women and 7 men with a mean age of 68.5 years, received
an average of 36.4 hours of EECP. CCS improved in all patients; the average baseline
class of 3.8 improved to an early CCS of 1.4 [p< 0.05] and 6.3 month CCS of 1.2
[p<0.05]. ST obtained a mean of 5.0 months post EECP showed complete resolution of
defects in 16/17 cases [p<0.05]. There was a durable reduction in angina in 20/21
patients at a mean 12.9 months of follow-up. With up to 19 months of follow-up only 1
patient had an adverse event [heart failure requiring admission] and increasing angina
[treated with EECP].
Conclusions: Microvascular angina is effectively treated with EECP. There is a reduction
in angina and provokable ischemia. The effect is durable with a low incidence of recurrent
angina one year post treatment and few adverse cardiovascular events.
